AltMountain

Artia Global Partners LP

Miami, FL · CRD 322091
Hedge fund manager

Artia Global Partners LP is an SEC-registered investment adviser based in Miami, FL that reports managing 1 hedge fund on Form ADV. It reports $778.9 million in regulatory assets under management. Its private funds, of all types, hold $778.9 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +3.7% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +13.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$778.9 millionForm ADV Item 5.F
Gross assets of private funds
$778.9 millionAll private fund types, Form ADV
Hedge funds managed
11 private funds in total
Employees
5Form ADV Item 5.A
Registration
SEC-registered adviserCRD 322091
Latest Form ADV
03/31/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+3.7%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+13.7%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$526.0 million47 positions, 2026-06-30
$82$110$137Q3 2024Q1 2025Q3 2025Q1 202613F est. $114S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+8.8%+14.8%
Q1 2026-4.7%-4.6%
Q4 2025+0.6%+2.4%
Q3 2025+20.0%+7.8%
Q2 2025+7.1%+10.4%
Q1 2025+3.3%-4.5%
Q4 2024-16.5%+2.1%
Q3 2024-1.7%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 50 share positions ($491,788,717) reported by Artia Global Partners LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Insmed Inc13.67%
  • Revolution Medicines Inc7.74%
  • Abivax SA7.33%
  • Brightspring Health Svcs Inc7.04%
  • Trevi Therapeutics Inc6.44%
  • Argenx SE5.80%
  • Travere Therapeutics Inc4.77%
  • Alkermes PLC3.70%
  • Guardant Health Inc3.51%
  • Astrazeneca PLC3.23%
StockValue% of 13F portfolioSharesShares vs prior quarter
Insmed Inc$67,234,39513.67%589,052Unchanged
Revolution Medicines Inc$38,053,1517.74%185,390Unchanged
Abivax SA$36,069,8177.33%364,268-29.47%
Brightspring Health Svcs Inc$34,614,3227.04%609,944+17.91%
Trevi Therapeutics Inc$31,659,4016.44%2,210,852Unchanged
Argenx SE$28,517,0245.80%29,739Unchanged
Travere Therapeutics Inc$23,463,2684.77%398,493+17.54%
Alkermes PLC$18,192,0213.70%448,964Unchanged
Guardant Health Inc$17,248,1253.51%96,704+153.82%
Astrazeneca PLC$15,884,7733.23%98,376Unchanged
Quest Diagnostics Inc$15,177,9853.09%65,122Unchanged
Dianthus Therapeutics Inc$14,592,9672.97%165,735+1.68%
Revvity Inc$12,376,1402.52%80,948New
Newamsterdam Pharma Company$12,255,7242.49%503,936Unchanged
Merck & Co Inc$11,697,4552.38%80,500+72.38%
Johnson & Johnson$7,174,4541.46%27,100+19.91%
Bruker Corp$6,720,7911.37%103,796New
Biogen Inc$6,604,0541.34%29,237+58.58%
Edgewise Therapeutics Inc$6,543,7051.33%161,175+63.13%
Viking Therapeutics Inc$5,891,8311.20%180,731Unchanged
Rapport Therapeutics Inc$5,594,6691.14%166,508+20.22%
Thermo Fisher Scientific Inc$5,137,1311.04%7,610New
Absci Corporation$5,002,0621.02%464,444Unchanged
Roivant Sciences LTD$4,746,7860.97%129,800Unchanged
Cytokinetics Inc$4,659,8370.95%70,700Unchanged
Scholar Rock Hldg Corp$4,652,4910.95%96,285Unchanged
Belite Bio Inc$4,243,6320.86%24,989Unchanged
10X Genomics Inc$4,183,6680.85%46,300New
Ascendis Pharma A/s$4,041,7040.82%17,740Unchanged
Celcuity Inc$4,017,5090.82%50,522-14.83%
Grail Inc$3,531,0240.72%25,200New
Mineralys Therapeutics Inc$3,462,9140.70%137,800Unchanged
Enliven Therapeutics Inc$3,305,0640.67%72,100Unchanged
Protagonist Therapeutics Inc$3,233,5660.66%22,951Unchanged
Twist Bioscience Corp$2,956,5720.60%15,300New
Oruka Therapeutics Inc$2,781,8860.57%33,400Unchanged
United Therapeutics Corp Del$2,709,4500.55%5,000Unchanged
Kiniksa Pharmaceuticals Intl$2,178,6120.44%29,200Unchanged
Corcept Therapeutics Inc$2,074,1400.42%18,000New
Bright Minds Biosciences Inc$1,913,4370.39%38,407Unchanged
Eyepoint Inc$1,519,5620.31%464,698-39.42%
Recursion Pharmaceuticals In$1,381,0800.28%334,402New
Agilent Technologies Inc$999,3980.20%5,800New
Prokidney Corp$919,2150.19%553,744-69.35%
Praxis Precision Medicines I$728,0750.15%2,500Unchanged
Pepgen Inc$496,8840.10%205,324Unchanged
MBX Biosciences Inc$486,5460.10%8,300New
Spyre Therapeutics Inc$356,1200.07%4,000Unchanged
Ginkgo Bioworks Holdings Inc$262,2970.05%20,444New
Climb Bio Inc$241,9830.05%21,097New

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 12 new positions, 9 sold out, 9 increased, 4 reduced and 25 unchanged.

Number of positions (a count, not dollars)

  • New positions12
  • Increased9
  • Unchanged25
  • Reduced4
  • Sold out9

New positions

StockValueShares
Revvity Inc$12,376,14080,948
Bruker Corp$6,720,791103,796
Thermo Fisher Scientific Inc$5,137,1317,610
10X Genomics Inc$4,183,66846,300
Grail Inc$3,531,02425,200
Twist Bioscience Corp$2,956,57215,300
Corcept Therapeutics Inc$2,074,14018,000
Recursion Pharmaceuticals In$1,381,080334,402
Agilent Technologies Inc$999,3985,800
MBX Biosciences Inc$486,5468,300
Ginkgo Bioworks Holdings Inc$262,29720,444
Climb Bio Inc$241,98321,097

Sold out

StockValue at Jun 30, 2026Shares held then
Ionis Pharmaceuticals Inc$11,447,573144,376
Alumis Inc$7,838,284278,546
Sionna Therapeutics Inc$5,267,407119,741
Palisade Bio Inc$4,164,0471,992,367
Xenon Pharmaceuticals Inc$3,923,40065,000
Compass Therapeutics Inc$839,208383,200
Kodiak Sciences Inc$663,06017,019
Tenax Therapeutics Inc$612,26442,080
Nuvalent Inc$605,1504,900

Largest increases

StockChange in sharesChangeValue nowShares now
Guardant Health Inc+58,604+153.82%$17,248,12596,704
Brightspring Health Svcs Inc+92,629+17.91%$34,614,322609,944
Merck & Co Inc+33,800+72.38%$11,697,45580,500
Travere Therapeutics Inc+59,460+17.54%$23,463,268398,493
Edgewise Therapeutics Inc+62,375+63.13%$6,543,705161,175
Biogen Inc+10,800+58.58%$6,604,05429,237
Johnson & Johnson+4,500+19.91%$7,174,45427,100
Rapport Therapeutics Inc+28,000+20.22%$5,594,669166,508
Dianthus Therapeutics Inc+2,745+1.68%$14,592,967165,735

Largest reductions

StockChange in sharesChangeValue nowShares now
Abivax SA-152,179-29.47%$36,069,817364,268
Prokidney Corp-1,253,195-69.35%$919,215553,744
Eyepoint Inc-302,400-39.42%$1,519,562464,698
Celcuity Inc-8,794-14.83%$4,017,50950,522

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (1)

As reported in the adviser's Form ADV filed Mar 26, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌​⁠